Retatrutide
Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon receptors.
- Vial Size
- 40mg
- Molecular Weight
- ~4731 g/mol
- Half-life
- ~6 days (research-model estimates)
- Latest Lot Purity
- 99.49%
Mechanism of Action
Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon receptors. Research models examine its convergent effects on energy expenditure, glycemic regulation, and adiposity via the incretin/glucagon axis.
Research Context
- GLP-1 / GIP / GCG receptor pharmacology
- Energy-expenditure research models
- Glycemic regulation studies
- Body-composition research
Lot NX-037 · Verified at 99.49%
Plasma Profile & Protocol
Modelled plasma concentration over time, reconstitution calculator, and a literature-derived research protocol for Retatrutide.
Illustrative Bateman model derived from published half-life and absorption data. For research-context visualisation only.
Solve for syringe units assuming a U-100 insulin syringe. Defaults seeded from the Retatrutide monograph.
U-100 insulin syringe assumed (100 units = 1 mL). For research dosing visualisation only. Verify all dilutions independently.
- Typical Dose
- 2–8 mg
- Frequency
- Once weekly
- Cycle Length
- 12–24 weeks titrated
- Route
- Subcutaneous
Note ·Long-acting triagonist; titration recommended in research.
For Research Use Only · This monograph summarises publicly available research literature for educational, in-vitro and laboratory research purposes only. Nexora Labs products are not drugs, food, supplements, or cosmetics, and are not intended to diagnose, treat, cure or prevent any condition.